Efficacy, Safety and Pharmacokinetics of Gammaplex in Primary Immunodeficiency Diseases.

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Bio Products Laboratory
ClinicalTrials.gov Identifier:
NCT00278954
First received: January 18, 2006
Last updated: January 23, 2013
Last verified: January 2013
  Purpose

The main objective of this study is to see if GAMMAPLEX is efficacious with respect to Food and Drug Administration (FDA) minimal requirements (no more than 1 serious, acute, bacterial infection per subject per year) in subjects with Primary Immunodeficiency Diseases (PID). The secondary objectives are to assess the safety and tolerability of GAMMAPLEX and to determine if GAMMAPLEX has a pharmacokinetic (PK) profile comparable with that of intact Immunoglobulin G (IgG) in subjects with PID.


Condition Intervention Phase
Primary Immunodeficiency
Common Variable Hypogammaglobulinemia
X-linked Hypogammaglobulinemia
Hypogammaglobulinemia
Immunodeficiency With Hyper-IgM
Wiskott-Aldrich Syndrome
Biological: Gammaplex (Intravenous immunoglobulin)
Phase 3

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase III, Multicenter, Open-Label Study To Evaluate The Efficacy, Safety, and Pharmacokinetics of Gammaplex® in Primary Immunodeficiency Diseases

Resource links provided by NLM:


Further study details as provided by Bio Products Laboratory:

Primary Outcome Measures:
  • Number of Serious, Acute, Bacterial Infections (SABIs) Per Subject Per Year in Subjects With Primary Immunodeficiency Disease. [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
    By assessing the number of serious, acute, bacterial infections per subject per year in subjects with Primary Immunodeficiency disease.


Secondary Outcome Measures:
  • The Pharmacokinetic (PK) Half-Life of Immunoglobulin G (IgG) [ Time Frame: -5, 0, 60 minutes (min), 24, 48 hours (hrs), 4, 7, 14, 21 and 28 days ] [ Designated as safety issue: Yes ]
    Blood samples for PK analysis were obtained and analysed at 10 different time points, i.e. -5, 0, 60 minutes (min), 24, 48 hours (hrs), 4, 7, 14, 21 and 28 days, at an infusion visit following 6 months of treatment.

  • The Pharmacokinetic (PK) Clearance of Immunoglobulin G (IgG) [ Time Frame: -5, 0, 60 min, 24, 48 hrs, 4, 7, 14, 21 and 28 days ] [ Designated as safety issue: Yes ]
    Blood samples for PK analysis were obtained and analysed at 10 different time points, i.e. -5, 0, 60 minutes (min), 24, 48 hours (hrs), 4, 7, 14, 21 and 28 days, at an infusion visit following 6 months of treatment.

  • The Pharmacokinetic (PK) Volume of Distribution (Vz)of Immunoglobulin G (IgG) [ Time Frame: -5, 0, 60 min, 24, 48 hrs, 4, 7, 14, 21 and 28 days ] [ Designated as safety issue: Yes ]
    Blood samples for PK analysis were obtained and analysed at 10 different time points, i.e. -5, 0, 60 minutes (min), 24, 48 hours (hrs), 4, 7, 14, 21 and 28 days, at an infusion visit following 6 months of treatment.

  • The Pharmacokinetic (PK) Mean Residence Time (MRT) for Inmuunoglobulin G (IgG) [ Time Frame: -5, 0, 60 min, 24, 48 hrs, 4, 7, 14, 21 and 28 days ] [ Designated as safety issue: Yes ]
    Blood samples for PK analysis were obtained and analysed at 10 different time points, i.e. -5, 0, 60 minutes (min), 24, 48 hours (hrs), 4, 7, 14, 21 and 28 days, at an infusion visit following 6 months of treatment.


Enrollment: 50
Study Start Date: January 2006
Study Completion Date: November 2007
Primary Completion Date: November 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Gammaplex
Gammaplex
Biological: Gammaplex (Intravenous immunoglobulin)
GAMMAPLEX 5g/100 mL, dose is 300-800 mg/kg/infusion every 21 or 28 days, intravenously for 12 months.

Detailed Description:

Primary Efficacy Variable The primary variable is the number of serious, acute, bacterial infections/subject/year, and it will be based on the total of all of the following events as defined by the FDA: bacterial Pneumonia, bacteremia/sepsis, osteomyelitis/septic arthritis, visceral abscess, and bacterial meningitis.

Secondary Efficacy Variables Secondary efficacy will be determined by using the following variables: number of days of work/school missed because of infection per subject year; number and days of hospitalizations because of infection per subject year; number of visits to physicians for acute problems and/or number of visits to hospital emergency rooms per subject year; other infections documented by fever or a positive result on a radiograph and/or culture; number of infectious episodes per subject per year; number of days on therapeutic antibiotics.These data will be entered into the subject diary, confirmed by the physician, and entered on the electronic-CRF (e-CRF).

Safety Variables. The variables used to assess safety will be the following: adverse events (AEs); vital signs; clinical laboratory tests and Direct Coombs' Test; transmission of viruses; physical examination.

Test product, dose/mode of administration, batch number(s): The GAMMAPLEX dose is 300-800 mg/kg/infusion (milligram per killgram per infusion) every 21 or 28 days, intravenously. At least 2 batches will be used in this study and no more than 1 batch in any given infusion.

Duration of treatment:

The total duration of treatment is 12 months.

  Eligibility

Ages Eligible for Study:   3 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 1. The subject is 3 years of age or older, of either sex, belonging to any ethnic group, and above a minimum weight of 27.5 kg. This weight is based on the amount of blood required for testing. If subject is participating in the PK segment, the minimum weight required is 37 kg.

    2. The subject has a primary immunodeficiency disease, which has as a significant component of hypogammaglobulinemia and/or antibody deficiency (e.g. (exempli gratia / for example), common variable immunodeficiency, X-linked and autosomal forms of agammaglobulinemia, hyper-immunoglobulin M (hyper-IgM) syndrome, Wiskott-Aldrich Syndrome). Isolated deficiency of a single IgG subclass, or of specific antibodies without hypogammaglobulinemia per se, does not qualify for inclusion.

    3. The subject has been receiving licensed or investigational (Phase III or IIIb) immunoglobulin intravenous (IGIV) replacement therapy at a dose that has not changed by + 50% of the mean dose for at least 3 months before study entry and is between 300 and 800 mg/kg/infusion. The infusion interval must be between 21 and 28 days inclusive. The subject must have maintained a trough level at least 300 mg/dL (milligram per decilitre) above baseline serum IgG levels (defined as before initiation of any gamma globulin treatment for that subject). The trough level must be 600 mg/dL.

    4. Trough levels of IgG and dose of IGIV, treatment intervals, and the trade name of the IGIV treatments used for the last 2 consecutive routine (licensed or investigational product) must be documented for each subject before the first infusion in this study can be administered.

    5. If a subject is a female of child-bearing potential, she must have a negative result on an Human Chorionic Gonadotrophin (HCG)-based pregnancy test.

    6. If a subject is a female who is or becomes sexually active, she must practice contraception by using a method of proven reliability for the duration of the study.

    7. The subject is willing to comply with all aspects of the protocol, including blood sampling, for the duration of the study.

    8. The subject has signed an informed consent form (if at least 18 years old) or the subject's parent or legal guardian has signed the informed consent form. If appropriate, the subject has signed a child assent form (See Section 12.3).

Exclusion Criteria:

  • Subjects will be excluded if any of the following exclusion criteria are met:

    1. The subject has a history of any severe anaphylactic reaction to blood or any blood-derived product.
    2. The subject is known to be intolerant to any component of GAMMAPLEX, such as sorbitol (i.e.(id est / that is) , intolerance to fructose).
    3. The subject has selective immunoglobulin A (IgA) deficiency, history of reaction to products containing IgA, or has a history of antibodies to IgA.
    4. Subjects who have completed the study and subjects who have withdrawn cannot participate in the study for a second time.
    5. The subject is currently receiving, or has received, any investigational agent, other than an immune serum globulin (ISG) preparation that is being evaluated in a Phase III or IIIb study, within the prior 3 months.
    6. The subject has been exposed to blood or any blood product or derivative within the last 6 months, other than a commercially available IGIV or other forms of commercially available and licensed ISG or an ISG product that is in Phase III or IIIb studies.
    7. The subject is pregnant or is nursing.
    8. The subject is positive for any of the following at screening:

      • Serological test for Human immunodeficiency virus (HIV) 1&2, Hepatitis C virus (HCV), or Hepatitis B surface antigen (HBsAg)
      • Nucleic Acid test (NAT) for HCV
      • NAT for HIV
    9. The subject, at screening, has levels greater than 2.5 times the upper limit of normal as defined at the central laboratory of any of the following:

      • Alanine transaminase (ALT)
      • Aspartate transaminase (AST)
    10. The subject has a severe renal impairment (defined as serum creatinine greater than 2 times the upper limit of normal or Blood urea nitrogen (BUN) greater than 2.5 times the upper limit of normal for the range of the laboratory doing the analysis); the subject is on dialysis; the subject has a history of acute renal failure.
    11. The subject is known to abuse alcohol, opiates, psychotropic agents, or other chemicals or drugs, or has done so within the past 12 months.
    12. The subject has a history of deep vein thrombosis (DVT), or thrombotic complications of IGIV therapy.
    13. The subject suffers from any acute or chronic medical condition (e.g., renal disease or predisposing conditions for renal disease, coronary artery disease, or protein losing state) that, in the opinion of the investigator, may interfere with the conduct of the study.
    14. The subject has an acquired medical condition, such as chronic lymphocytic leukemia, lymphoma, multiple myeloma, chronic or recurrent neutropenia (Absolute neutrophil count (ANC) < 1000 x 109/L).
    15. The subject is receiving the following medication:

      • Immunosuppressive drugs
      • The subject is receiving the following medication: Steroids (long-term daily, >0.15 mg /kg/day of prednisone or prednisolone of equivalent dose of other corticosteroids) The requirement for burst or intermittent courses would not exclude the subject.
      • Immunomodulatory drugs
    16. The subject has non-controlled arterial hypertension (systolic blood pressure > 160 mmHg (millimeters of mercury) and/or diastolic blood pressure > 100 mmHg).
    17. The subject has anemia (hemoglobin < 10 g/dL) at screening.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00278954

Locations
United States, Florida
Allergy Associates of the Palm Beaches
North Palm Beach, Florida, United States, 33408
United States, Georgia
Family Allergy and Asthma Center PC
Atlanta, Georgia, United States, 30342
United States, Illinois
Rush University Medical Centre, University Consultants in Allergy & Immunology
Chicago, Illinois, United States, 60612
United States, New York
Childrens Hospital at Buffalo, Allergy Division
Buffalo, New York, United States, 14222
United States, Texas
Allergy, Asthma & Immunology Clinic, P.A.
Irving, Texas, United States, 75063
UCLA Medical Centre
Irving, Texas, United States, 75063
United States, Washington
University of Washington School of Medicine, Dept. of Pediatrics
Seattle, Washington, United States, 989109-5235
Sponsors and Collaborators
Bio Products Laboratory
Investigators
Principal Investigator: Melvin Berger, MD Rainbow Babies & Children's Hospital, Cleveland, Ohio
  More Information

Additional Information:
No publications provided

Responsible Party: Bio Products Laboratory
ClinicalTrials.gov Identifier: NCT00278954     History of Changes
Other Study ID Numbers: GMX01
Study First Received: January 18, 2006
Results First Received: May 29, 2009
Last Updated: January 23, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Bio Products Laboratory:
Primary Antibody Deficiency
Common variable hypogammaglobulinemia
X-linked hypogammaglobulinemia
Hypogammaglobulinemia
Immunodeficiency with hyper-IgM
Wiskott-Aldrich Syndrome

Additional relevant MeSH terms:
Immunologic Deficiency Syndromes
Wiskott-Aldrich Syndrome
Hyper-IgM Immunodeficiency Syndrome
Common Variable Immunodeficiency
Agammaglobulinemia
Immune System Diseases
Blood Coagulation Disorders, Inherited
Blood Coagulation Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphopenia
Leukopenia
Leukocyte Disorders
Genetic Diseases, Inborn
Genetic Diseases, X-Linked
Blood Protein Disorders
Lymphoproliferative Disorders
Lymphatic Diseases
Dysgammaglobulinemia
Immunoglobulins
Antibodies
Immunoglobulins, Intravenous
Rho(D) Immune Globulin
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on July 23, 2014